Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel Group, Prospective, Randomized, Double-blind, Two-arm, Single-center Study to Evaluate the Immunogenicity, Safety, and Tolerability of mRNA-1273 in Heterologous Prime-Boost With MVC-COV1901 in Adult Volunteers of 20 to 70 Years

NCT05079633 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT05079633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05079633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel Group, Prospective, Randomized, Double-blind, Two-arm, Single-center Study to Evaluate the Immunogenicity, Safety, and Tolerability of mRNA-1273 in Heterologous Prime-Boost With MVC-COV1901 in Adult Volunteers of 20 to 70 Years
Lead sponsor
National Taiwan University Hospital
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2021
Completion date
January 10, 2023
Enrollment
220 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19 vaccine